CY1118840T1 - Πρωτοτυπα πεπτιδια για θεραπευτικη και προληπτικη αγωγη ανοσοσχετιζομενων διαταραχων, που περιλαμβανει θεραπευτικη και προληπτικη αγωγη λοιμωξης διαμορφωνοντας εγγενη ανοσια - Google Patents
Πρωτοτυπα πεπτιδια για θεραπευτικη και προληπτικη αγωγη ανοσοσχετιζομενων διαταραχων, που περιλαμβανει θεραπευτικη και προληπτικη αγωγη λοιμωξης διαμορφωνοντας εγγενη ανοσιαInfo
- Publication number
- CY1118840T1 CY1118840T1 CY20171100218T CY171100218T CY1118840T1 CY 1118840 T1 CY1118840 T1 CY 1118840T1 CY 20171100218 T CY20171100218 T CY 20171100218T CY 171100218 T CY171100218 T CY 171100218T CY 1118840 T1 CY1118840 T1 CY 1118840T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptide
- therapeutic
- preventive
- subject
- nucleic acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 230000002950 deficient Effects 0.000 title 1
- 238000009117 preventive therapy Methods 0.000 title 1
- 230000015788 innate immune response Effects 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
Abstract
Σε μία πτυχή, η παρούσα εφεύρεση παρέχει απομονωμένα πρωτότυπα πεπτίδια που μπορούν να χρησιμοποιηθούν για να διαμορφώνουν εγγενή ανοσία σε υποκείμενο, και/ή για την θεραπευτική αγωγή ανοσοσχετιζόμενης διαταραχής, που περιλαμβάνει θεραπευτική και προληπτική αγωγή λοίμωξη διαμορφώνοντας εγγενή ανοσία. Παρέχεται επίσης παράγοντας αντιδραστικός με το πεπτίδιο, φαρμακευτική σύνθεση που περιλαμβάνει το πεπτίδιο, απομονωμένο μόριο νουκλεϊκού οξέος που κωδικοποιεί το πεπτίδιο, ανασυνδυασμένο κατασκεύασμα νουκλεϊκού οξέος που περιλαμβάνει το μόριο νουκλεϊκού οξέος, τουλάχιστον ένα κύτταρο-ξενιστής που περιλαμβάνει το ανασυνδυασμένο κατασκεύασμα νουκλεϊκού οξέος, και μέθοδος παραγωγής του πεπτιδίου χρησιμοποιώντας το κύτταρο-ξενιστή. Η παρούσα εφεύρεση παρέχει επιπλέον μέθοδο για θεραπευτική και/ή προληπτική αγωγή λοίμωξης σε υποκείμενο χορηγώντας το πεπτίδιο της εφεύρεσης στο υποκείμενο, διαμορφώνοντας έτσι την εγγενή ανοσία στο υποκείμενο. Επιπροσθέτως, η παρούσα εφεύρεση παρέχει μέθοδο πρόβλεψης της αποκριτικότητας υποκειμένου σε θεραπευτική αγωγή με πεπτίδιο της εφεύρεσης.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72296205P | 2005-10-04 | 2005-10-04 | |
| US72295905P | 2005-10-04 | 2005-10-04 | |
| US72295805P | 2005-10-04 | 2005-10-04 | |
| EP06790808A EP1931779A4 (en) | 2005-10-04 | 2006-10-04 | NOVEL PEPTIDES FOR THE TREATMENT AND PREVENTION OF IMMUNITY-RELATED DISORDERS, INCLUDING THE TREATMENT AND PREVENTION OF INFECTION BY MODULATION OF INITIATED IMMUNITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118840T1 true CY1118840T1 (el) | 2018-01-10 |
Family
ID=37905947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100218T CY1118840T1 (el) | 2005-10-04 | 2017-02-17 | Πρωτοτυπα πεπτιδια για θεραπευτικη και προληπτικη αγωγη ανοσοσχετιζομενων διαταραχων, που περιλαμβανει θεραπευτικη και προληπτικη αγωγη λοιμωξης διαμορφωνοντας εγγενη ανοσια |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8124721B2 (el) |
| EP (6) | EP2447368A3 (el) |
| JP (2) | JP2009509552A (el) |
| KR (1) | KR101410685B1 (el) |
| CN (1) | CN101351554B (el) |
| AU (1) | AU2006299682B2 (el) |
| BR (1) | BRPI0616936B8 (el) |
| CA (1) | CA2625183C (el) |
| CY (1) | CY1118840T1 (el) |
| DK (2) | DK2236608T3 (el) |
| ES (1) | ES2609520T3 (el) |
| HU (1) | HUE031989T2 (el) |
| IL (1) | IL190601A (el) |
| LT (1) | LT2236608T (el) |
| MX (1) | MX2009003636A (el) |
| MY (1) | MY157947A (el) |
| PL (1) | PL2236608T3 (el) |
| PT (1) | PT2236608T (el) |
| RU (2) | RU2507213C2 (el) |
| SI (1) | SI2236608T1 (el) |
| WO (1) | WO2007038876A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2609520T3 (es) | 2005-10-04 | 2017-04-20 | Soligenix, Inc. | Péptidos novedosos para tratar y prevenir trastornos relacionados con el sistema inmunitario, incluyendo el tratamiento y la prevención de infecciones modulando la inmunidad innata |
| AU2007304847A1 (en) * | 2006-10-04 | 2008-04-10 | Inimex Pharmaceuticals, Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| WO2014169274A2 (en) * | 2013-04-12 | 2014-10-16 | Yale University | Modified proteins and methods of use thereof |
| US11311598B2 (en) * | 2013-09-13 | 2022-04-26 | Soligenix, Inc. | Peptides and analogs for use in the treatment of oral mucositis |
| MY177930A (en) * | 2013-09-13 | 2020-09-28 | Soligenix Inc | Novel peptides and analogs for use in the treatment of oral mucositis |
| US20150148304A1 (en) * | 2013-10-24 | 2015-05-28 | Soligenix, Inc. | Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome |
| BR112018007483A2 (pt) * | 2015-10-16 | 2018-10-23 | Arsanis Biosciences Gmbh | ?anticorpo monoclonal bactericida contra klebsiella pneumoniae, uma preparação farmacêutica para uso médico e diagnóstico; ácido nucleico codificante; e método de produção? |
| WO2018165764A1 (en) * | 2017-03-16 | 2018-09-20 | Microsintesis Inc. | Compositions and methods involving probiotic molecules |
| WO2024038888A1 (ja) * | 2022-08-19 | 2024-02-22 | 森永乳業株式会社 | 組成物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| WO1994006465A1 (en) | 1992-09-16 | 1994-03-31 | The University Of Tennessee Research Corporation | Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
| US5916872A (en) * | 1996-07-24 | 1999-06-29 | Intrabiotics Pharmaceuticals, Inc. | Cyclic peptides having broad spectrum antimicrobial activity |
| US20030176357A1 (en) | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| US7504490B1 (en) * | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
| EP2275552B1 (en) * | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
| GB9929464D0 (en) * | 1999-12-13 | 2000-02-09 | Proteom Ltd | Complementary peptide ligande generated from the human genome |
| IL134830A0 (en) | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
| US20090062512A1 (en) | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| FR2825095B1 (fr) * | 2001-05-28 | 2003-09-26 | Dev Des Antigenes Combinatoire | Dispositif de presentation de polypeptides, utilisable comme "puce" pour la detection miniaturisee de molecules |
| CA2449168A1 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
| US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| CA2424645A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | New use of dipeptidyl peptidase iv inhibitors |
| US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| GB0125445D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| KR20040077669A (ko) * | 2001-12-03 | 2004-09-06 | 유니버시티 오브 브리티시 콜롬비아 | 선천 면역의 작동체 |
| US7507787B2 (en) | 2001-12-03 | 2009-03-24 | The University Of British Columbia | Effectors of innate immunity |
| WO2003063759A2 (en) | 2002-01-31 | 2003-08-07 | Peptor Ltd. | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
| US8535672B2 (en) | 2002-04-04 | 2013-09-17 | Yissum Research Development Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof |
| US7618788B2 (en) | 2002-05-10 | 2009-11-17 | Millipore Corporation | Proteome epitope tags and methods of use thereof in protein modification analysis |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US20040037809A1 (en) | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
| EP1578432A4 (en) | 2002-10-03 | 2008-07-30 | Epimmune Inc | HLA BINDING PEPTIDES AND USES THEREOF |
| CA2538085C (en) | 2003-09-12 | 2011-03-15 | Novozymes A/S | Synthetic antimicrobial polypeptides |
| WO2005038000A2 (en) * | 2003-10-17 | 2005-04-28 | Pecos Labs, Inc. | T cell epitopes useful in mycobacterium tuberculosis vaccine and as diagnostic tools and methods for identifying same |
| AU2005215943A1 (en) * | 2004-03-01 | 2005-09-09 | Peptera Pharmaceutical Ltd. | Casein derived peptides and therapeutic uses thereof |
| CA2576293C (en) | 2004-07-12 | 2016-10-04 | Nicola J. Mabjeesh | Agents capable of downregulating an msf-a-dependent hif-1alpha and use thereof in cancer treatment |
| WO2006005190A1 (en) * | 2004-07-14 | 2006-01-19 | Inimex Pharmaceuticals Inc. | Method of screening for protection from microbial infection |
| EP1626059A1 (en) | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| CA2629751A1 (en) | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
| AU2006239141A1 (en) | 2005-04-26 | 2006-11-02 | Karyon-Ctt Ltd | Diagnostic and therapeutic agents |
| ES2609520T3 (es) * | 2005-10-04 | 2017-04-20 | Soligenix, Inc. | Péptidos novedosos para tratar y prevenir trastornos relacionados con el sistema inmunitario, incluyendo el tratamiento y la prevención de infecciones modulando la inmunidad innata |
| AU2007304847A1 (en) | 2006-10-04 | 2008-04-10 | Inimex Pharmaceuticals, Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
-
2006
- 2006-10-04 ES ES10003191.3T patent/ES2609520T3/es active Active
- 2006-10-04 EP EP11182636A patent/EP2447368A3/en not_active Withdrawn
- 2006-10-04 HU HUE10003191A patent/HUE031989T2/en unknown
- 2006-10-04 EP EP10003191.3A patent/EP2236608B1/en active Active
- 2006-10-04 CN CN200680045440.2A patent/CN101351554B/zh active Active
- 2006-10-04 PL PL10003191T patent/PL2236608T3/pl unknown
- 2006-10-04 DK DK10003191.3T patent/DK2236608T3/en active
- 2006-10-04 EP EP11182635.0A patent/EP2447367B1/en active Active
- 2006-10-04 RU RU2008115390/10A patent/RU2507213C2/ru active
- 2006-10-04 EP EP06790808A patent/EP1931779A4/en not_active Withdrawn
- 2006-10-04 AU AU2006299682A patent/AU2006299682B2/en active Active
- 2006-10-04 PT PT100031913T patent/PT2236608T/pt unknown
- 2006-10-04 WO PCT/CA2006/001650 patent/WO2007038876A1/en not_active Ceased
- 2006-10-04 LT LTEP10003191.3T patent/LT2236608T/lt unknown
- 2006-10-04 BR BRPI0616936A patent/BRPI0616936B8/pt active IP Right Grant
- 2006-10-04 JP JP2008533838A patent/JP2009509552A/ja not_active Withdrawn
- 2006-10-04 SI SI200632149A patent/SI2236608T1/sl unknown
- 2006-10-04 EP EP11182638A patent/EP2447369A3/en not_active Withdrawn
- 2006-10-04 CA CA2625183A patent/CA2625183C/en active Active
- 2006-10-04 US US12/083,086 patent/US8124721B2/en active Active
- 2006-10-04 DK DK11182635.0T patent/DK2447367T3/en active
- 2006-10-04 KR KR1020087010890A patent/KR101410685B1/ko active Active
-
2007
- 2007-04-03 EP EP07719467A patent/EP2076596A4/en not_active Withdrawn
- 2007-04-03 RU RU2009117490/10A patent/RU2009117490A/ru not_active Application Discontinuation
- 2007-04-03 MX MX2009003636A patent/MX2009003636A/es not_active Application Discontinuation
-
2008
- 2008-04-03 IL IL190601A patent/IL190601A/en active IP Right Grant
- 2008-04-03 MY MYPI20080957A patent/MY157947A/en unknown
-
2012
- 2012-01-27 US US13/360,163 patent/US9416157B2/en active Active
- 2012-08-08 JP JP2012175961A patent/JP5780600B2/ja active Active
-
2017
- 2017-02-17 CY CY20171100218T patent/CY1118840T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118840T1 (el) | Πρωτοτυπα πεπτιδια για θεραπευτικη και προληπτικη αγωγη ανοσοσχετιζομενων διαταραχων, που περιλαμβανει θεραπευτικη και προληπτικη αγωγη λοιμωξης διαμορφωνοντας εγγενη ανοσια | |
| ES2671493T3 (es) | Tratamiento con multiproteasa para el dolor crónico | |
| ES2389670T3 (es) | Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica desfuncional | |
| RU2012101485A (ru) | Биспецифические четырехвалентные антигенсвязывающие белки | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| AR032743A1 (es) | Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| WO2022150732A3 (en) | Chimeric receptor therapy | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| RU2018132639A (ru) | Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения | |
| AR110031A1 (es) | Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa | |
| EA202192460A1 (ru) | Синтетические нейромодуляторные пептиды | |
| Li et al. | Inhibition of chemokine CX3CL1 in spinal cord mediates the electroacupuncture-induced suppression of inflammatory pain | |
| WO2008040111A8 (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity | |
| BR112022014552A2 (pt) | Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante |